Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 6/2014

01-06-2014 | Original Article – Cancer Research

IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma

Authors: Shuai Hu, Xiaofeng Wu, Bo Zhou, Zhenchao Xu, Jianjie Qin, Hao Lu, Ling Lv, Yun Gao, Lei Deng, Jie Yin, Guoqiang Li

Published in: Journal of Cancer Research and Clinical Oncology | Issue 6/2014

Login to get access

Abstract

Purpose

Insulin-like growth factor 2 mRNA-binding protein 3 (IMP3) is reported to be re-expressed in malignant tumors and can regulate the expression of multiple genes related to tumor invasion. CD44 standard isoform (CD44s) has been reported to play an important role in facilitating tumor invasion. In this text, we investigate the regulatory function of IMP3 on CD44s and the role of IMP3 and CD44s in predicting the outcomes of patients with hepatocellular carcinoma.

Methods

IMP3 and CD44s were measured in hepatocellular carcinoma (HCC) tissues by immunohistochemical assay, and survival analysis was conducted among 128 patients. Moreover, we studied the effect of IMP3 on the expression of CD44s and the biological functions of tumor cells in HCC cell lines.

Results

Our results showed that the expression of IMP3 was significantly correlated with CD44s expression (r = 0.505, P < 0.001), and both of them correlated with high AFP level, advanced tumor stage and grade, portal vein tumor thrombus, and early tumor recurrence or metastasis. The results of survival analysis exhibited that the 1-, 3-, 5-year disease-free and overall survival rates significantly reduced in IMP3- and CD44s-positive patients, and IMP3 combined with CD44s was an independent prognostic risk factor for HCC. In vitro assay, our results showed that IMP3 promoted HepG2 and MHCC97H cells invading and migrating via regulating CD44s expression.

Conclusions

Our findings suggest that IMP3 facilitates HCC aggressiveness through regulating CD44s expression, and IMP3 combined with CD44s can be as a new predictor for unfavorable prognosis in HCC patients.
Literature
go back to reference Cornejo K, Shi M, Jiang Z (2012) Oncofetal protein IMP3: a useful diagnostic biomarker for leiomyosarcoma. Hum Pathol 43(10):1567–1572PubMedCrossRef Cornejo K, Shi M, Jiang Z (2012) Oncofetal protein IMP3: a useful diagnostic biomarker for leiomyosarcoma. Hum Pathol 43(10):1567–1572PubMedCrossRef
go back to reference Endo K, Terada T (2000) Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol 32(1):78–84PubMedCrossRef Endo K, Terada T (2000) Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol 32(1):78–84PubMedCrossRef
go back to reference Findeis-Hosey JJ, Yang Q, Spaulding BO, Wang HL, Xu H (2010) IMP3 expression is correlated with histologic grade of lung adenocarcinoma. Hum Pathol 41(4):477–484PubMedCrossRef Findeis-Hosey JJ, Yang Q, Spaulding BO, Wang HL, Xu H (2010) IMP3 expression is correlated with histologic grade of lung adenocarcinoma. Hum Pathol 41(4):477–484PubMedCrossRef
go back to reference Furihata T, Sawada T, Kita J, Iso Y, Kato M, Rokkaku K et al (2008) Serum alpha-fetoprotein level per tumor volume reflects prognosis in patients with hepatocellular carcinoma after curative hepatectomy. Hepatogastroenterology 55(86–87):1705–1709PubMed Furihata T, Sawada T, Kita J, Iso Y, Kato M, Rokkaku K et al (2008) Serum alpha-fetoprotein level per tumor volume reflects prognosis in patients with hepatocellular carcinoma after curative hepatectomy. Hepatogastroenterology 55(86–87):1705–1709PubMed
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):134CrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):134CrossRef
go back to reference Jeng YM, Chang CC, Hu FC, Chou HY, Kao HL, Wang TH et al (2008) RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology 48(4):1118–1127PubMedCrossRef Jeng YM, Chang CC, Hu FC, Chou HY, Kao HL, Wang TH et al (2008) RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology 48(4):1118–1127PubMedCrossRef
go back to reference Jiang Z, Chu PG, Woda BA, Rock KL, Liu Q, Hsieh CC et al (2006) Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 7(7):556–564PubMedCrossRef Jiang Z, Chu PG, Woda BA, Rock KL, Liu Q, Hsieh CC et al (2006) Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 7(7):556–564PubMedCrossRef
go back to reference Jiang Z, Lohse CM, Chu PG, Wu CL, Woda BA, Rock KL et al (2008) Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer 112(12):2676–2682PubMedCentralPubMedCrossRef Jiang Z, Lohse CM, Chu PG, Wu CL, Woda BA, Rock KL et al (2008) Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer 112(12):2676–2682PubMedCentralPubMedCrossRef
go back to reference Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12(10):1167–1174PubMedCrossRef Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12(10):1167–1174PubMedCrossRef
go back to reference Kishi Y, Hasegawa K, Sugawara Y, Kokudo N (2011) Hepatocellular carcinoma: current management and future development-improved outcomes with surgical resection. Int J Hepatol 2011:728103PubMedCentralPubMedCrossRef Kishi Y, Hasegawa K, Sugawara Y, Kokudo N (2011) Hepatocellular carcinoma: current management and future development-improved outcomes with surgical resection. Int J Hepatol 2011:728103PubMedCentralPubMedCrossRef
go back to reference Köbel M, Xu H, Bourne PA, Spaulding BO, Shihle M, Mao TL et al (2009) IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol 22(3):469–475PubMedCrossRef Köbel M, Xu H, Bourne PA, Spaulding BO, Shihle M, Mao TL et al (2009) IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol 22(3):469–475PubMedCrossRef
go back to reference Li D, Yan D, Tang H, Zhou C, Fan J, Li S et al (2009) IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol 16(12):3499–3506PubMedCrossRef Li D, Yan D, Tang H, Zhou C, Fan J, Li S et al (2009) IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol 16(12):3499–3506PubMedCrossRef
go back to reference Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H et al (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17(2):211–215PubMedCentralPubMedCrossRef Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H et al (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17(2):211–215PubMedCentralPubMedCrossRef
go back to reference Lochhead P, Imamura Y, Morikawa T, Kuchiba A, Yamauchi M, Liao X et al (2012) Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer 48(18):3405–3413PubMedCentralPubMedCrossRef Lochhead P, Imamura Y, Morikawa T, Kuchiba A, Yamauchi M, Liao X et al (2012) Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer 48(18):3405–3413PubMedCentralPubMedCrossRef
go back to reference Mima K, Okabe H, Ishimoto T, Hayashi H, Nakagawa S, Kuroki H et al (2012) CD44s regulates the TGF-β-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res 72(13):3414–3423PubMedCrossRef Mima K, Okabe H, Ishimoto T, Hayashi H, Nakagawa S, Kuroki H et al (2012) CD44s regulates the TGF-β-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res 72(13):3414–3423PubMedCrossRef
go back to reference Mueller-Pillasch F, Pohl B, Wilda M, Lacher U, Beil M, Wallrapp C et al (1999) Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 88(1):95–99PubMedCrossRef Mueller-Pillasch F, Pohl B, Wilda M, Lacher U, Beil M, Wallrapp C et al (1999) Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 88(1):95–99PubMedCrossRef
go back to reference Nemunaitis J, Meyers T, Senzer N, Cunningham C, West H, Vallieres E et al (2006) Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Ther 13(6):1185–1191PubMedCrossRef Nemunaitis J, Meyers T, Senzer N, Cunningham C, West H, Vallieres E et al (2006) Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Ther 13(6):1185–1191PubMedCrossRef
go back to reference Olsen SK, Brown RS, Siegel AB (2010) Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol 3(1):55–66PubMedCentralPubMedCrossRef Olsen SK, Brown RS, Siegel AB (2010) Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol 3(1):55–66PubMedCentralPubMedCrossRef
go back to reference Orian-Rousseau V (2010) CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46(7):1271–1277PubMedCrossRef Orian-Rousseau V (2010) CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46(7):1271–1277PubMedCrossRef
go back to reference Pham PV, Phan NL, Nguyen NT, Truong NH, Duong TT, Le DV et al (2011) Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J Transl Med 9:209PubMedCentralPubMedCrossRef Pham PV, Phan NL, Nguyen NT, Truong NH, Duong TT, Le DV et al (2011) Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J Transl Med 9:209PubMedCentralPubMedCrossRef
go back to reference Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA, Xu H (2008) IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol 21(4):431–437PubMedCrossRef Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA, Xu H (2008) IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol 21(4):431–437PubMedCrossRef
go back to reference Schaeffer DF, Owen DR, Lim HJ, Buczkowski AK, Chung SW, Scudamore CH et al (2010) Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer 10:59PubMedCentralPubMedCrossRef Schaeffer DF, Owen DR, Lim HJ, Buczkowski AK, Chung SW, Scudamore CH et al (2010) Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer 10:59PubMedCentralPubMedCrossRef
go back to reference Sitnikova L, Mendese G, Liu Q, Woda BA, Lu D, Dresser K et al (2008) IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res 14(6):1701–1706PubMedCrossRef Sitnikova L, Mendese G, Liu Q, Woda BA, Lu D, Dresser K et al (2008) IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res 14(6):1701–1706PubMedCrossRef
go back to reference So JY, Smolarek AK, Salerno DM, Maehr H, Uskokovic M, Liu F et al (2013) Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer. PLoS ONE 8(1):e54020PubMedCentralPubMedCrossRef So JY, Smolarek AK, Salerno DM, Maehr H, Uskokovic M, Liu F et al (2013) Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer. PLoS ONE 8(1):e54020PubMedCentralPubMedCrossRef
go back to reference Tanaka S, Arii S (2012) Molecular targeted therapies in hepatocellular carcinoma. Semin Oncol 39(4):486–492PubMedCrossRef Tanaka S, Arii S (2012) Molecular targeted therapies in hepatocellular carcinoma. Semin Oncol 39(4):486–492PubMedCrossRef
go back to reference Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH et al (2004) A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 130(4):187–196PubMedCrossRef Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH et al (2004) A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 130(4):187–196PubMedCrossRef
go back to reference Vikesaa J, Hansen TV, Jonson L, Borup R, Wewer UM, Christiansen J et al (2006) RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 25(7):1456–1468PubMedCentralPubMedCrossRef Vikesaa J, Hansen TV, Jonson L, Borup R, Wewer UM, Christiansen J et al (2006) RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 25(7):1456–1468PubMedCentralPubMedCrossRef
go back to reference Wachter DL, Kristiansen G, Soll C, Hellerbrand C, Breuhahn K, Fritzsche F et al (2012) Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value. Histopathology 60(2):278–286PubMedCrossRef Wachter DL, Kristiansen G, Soll C, Hellerbrand C, Breuhahn K, Fritzsche F et al (2012) Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value. Histopathology 60(2):278–286PubMedCrossRef
go back to reference Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A (2009) IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum Pathol 40(11):1528–1533PubMedCrossRef Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A (2009) IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum Pathol 40(11):1528–1533PubMedCrossRef
go back to reference Wu Y, Zhang X, Zhou H, Chen D, Xie H, Mu Y et al (2013) Factor VIIa regulates the expression of caspase-3, MMP-9, and CD44 in SW620 colon cancer cells involving PAR2/MAPKs/NF-kappaB signaling pathways. Cancer Invest 31(1):7–16PubMedCrossRef Wu Y, Zhang X, Zhou H, Chen D, Xie H, Mu Y et al (2013) Factor VIIa regulates the expression of caspase-3, MMP-9, and CD44 in SW620 colon cancer cells involving PAR2/MAPKs/NF-kappaB signaling pathways. Cancer Invest 31(1):7–16PubMedCrossRef
go back to reference Yaniv K, Yisraeli JK (2002) The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. Gene 287(1–2):49–54PubMedCrossRef Yaniv K, Yisraeli JK (2002) The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. Gene 287(1–2):49–54PubMedCrossRef
go back to reference Yuan RH, Wang CC, Chou CC, Chang KJ, Lee PH, Jeng YM (2009) Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma. Ann Surg Oncol 16(6):1711–1719PubMedCrossRef Yuan RH, Wang CC, Chou CC, Chang KJ, Lee PH, Jeng YM (2009) Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma. Ann Surg Oncol 16(6):1711–1719PubMedCrossRef
go back to reference Zhou ZJ, Dai Z, Zhou SL, Fu XT, Zhao YM, Shi YH et al (2013) Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma. Int J Cancer 132(5):1080–1089PubMedCrossRef Zhou ZJ, Dai Z, Zhou SL, Fu XT, Zhao YM, Shi YH et al (2013) Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma. Int J Cancer 132(5):1080–1089PubMedCrossRef
Metadata
Title
IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma
Authors
Shuai Hu
Xiaofeng Wu
Bo Zhou
Zhenchao Xu
Jianjie Qin
Hao Lu
Ling Lv
Yun Gao
Lei Deng
Jie Yin
Guoqiang Li
Publication date
01-06-2014
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 6/2014
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-014-1639-x

Other articles of this Issue 6/2014

Journal of Cancer Research and Clinical Oncology 6/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.